Agios reports Q2 2026 results, sickle cell filing gets FDA priority review
Agios said its mitapivat sNDA in sickle cell disease has a PDUFA date of November 1, 2026, while it licensed cevidoplenib and dropped tebapivat from two programs.
SEC filing
Latest
1 story